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Indwelling silicone valves called voice prostheses (VPs) are the gold standard for speech
rehabilitation in patients with laryngeal cancer following total laryngectomy. Reported
VP lifespans amongst these patients are highly variable but when devices fail patients
experience loss of voice and an increase risk of chest infection. Early failure of VP
is a current clinical concern that is associated with regular hospital visits, reduced
quality of life and associated medical cost. Poly-microbial biofilms comprised of both
bacterial and fungal microorganisms readily colonize VPs and are linked to loss of device
performance and its early failure in addition to providing a reservoir for potential infection.
Our detailed analysis of poly-microbial biofilm composition on 159 early failing VPs from
48 total laryngectomy patients confirmed Candida albicans as the predominant fungal
species and Staphylococcus aureus as the most common bacterial colonizer within
our patient cohort. Using a combination of microbiological analysis, patient data and
a high-throughput antifungal test assay mimicking in vivo conditions we established
an evidence based precision antifungal treatment approach to VP management. Our
approach has allowed us to implement a personalized VP management pathway, which
increases device in situ lifespan by an average of 270%. Our study represents a
significant step forward in both our understanding of the cause of VP failure and a new
effective treatment pathway that offers tangible benefit to patients.
Keywords: Candida, voice prosthesis, laryngectomy, speech therapy, microbiology, antifungal
INTRODUCTION
Head and neck cancer is the sixth most common cancer worldwide and the eighth most
common cancer in the United Kingdom with 650,000 new cases (12,000 in the United Kingdom)
and 350,000 deaths (4,000 in the United Kingdom) attributed to it each year worldwide
(Leonhard and Schneider-Stickler, 2015; Cancer Research UK, 2018). Laryngeal malignancy is
the most frequent head and neck cancer, making up 26.2% of newly diagnosed male cases
and 13.1% of female cases in the United Kingdom (Cancer Research UK, 2018). Laryngeal
malignancy is treated with radiotherapy if it is diagnosed at an early stage, however, at later
stages treatment involves surgery often in conjunction with radiotherapy (Brook, 2013). The
majority of head and neck cancers are diagnosed at an advanced stage; for example 62% of
new diagnoses in Northern Ireland are reported to be at Stage III or Stage IV (Stage IV
alone accounts for 45%) (Cancer Research UK, 2018). Late diagnosis means that many cases of
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laryngeal cancer have to undergo a partial or total laryngectomy.
It has been estimated that there are currently 50,000–60,000
laryngectomees living in the United States (Brook, 2013).
Following a laryngectomy, the patient will no longer be
able to form speech on their own. The gold standard for
speech rehabilitation is tracheesophageal speech which requires
the use of a small silicone valve known as a voice prosthesis
(VP) (Bunting, 2004). Voice prostheses are susceptible to
colonization by microbial biofilms (Busscher et al., 1997a).
Such contamination may be enhanced by the environment of
the esophagus, e.g., foods, liquids (including saliva), humidity
and constant temperature (Holmes et al., 2014; Talpaert et al.,
2015), and device failure has been attributed to such microbial
growth as it can prevent valve closure (Leunisse et al., 2001;
Oosterhof et al., 2005) and leakage of esophageal contents into
the trachea. A loss of valve functionality leads to poor speech
and requires replacement of the device (Ticac et al., 2010;
Leonhard and Schneider-Stickler, 2015). Moreover, the microbial
colonization may act as a reservoir of potential pathogens which,
subsequent to aspiration, may lead to life-threatening infections
such as pneumonia (Delank and Scheuermann, 2008). The mean
VP lifespan is highly variable across different studies and has
historically been reported as being between 120 and 200 days
(Schafer et al., 2001; Sayed et al., 2012). However, a recent large-
scale study which analyzed the lifespan of 3648 VPs reported an
average of 86 days (Lewin et al., 2017). A number of strategies
have been proposed to increase VP lifespan, such as the use
of magnets to support the closing of the valve (Hilgers et al.,
2003) and the incorporation of compounds, for example silver
oxide, within the VP material to prevent microbial colonization
(Hilgers et al., 2009). VPs containing magnets such as the Provox
ActiValve have been shown to have longer in situ lifespans than
other models (Kress et al., 2014; Lewin et al., 2017). However,
overall, the levels of success with these approaches has been
variable and importantly the average VP device lifespan has not
significantly increased over the last 10 years (Lewin et al., 2017).
Co-colonization of VPs by bacterial and fungal species
within poly-microbial biofilms is commonly reported. However,
it is not clear to what extent yeast and bacterial biofilm
colonization contributes to early VP failure, nor how effective
their prevention may be in extending device lifespan. Medically,
biofilms are of particular importance because it is thought
that a significant percentage of human microbial infections
include biofilm formation (Costerton et al., 1999; Donlan,
2001a,b). Furthermore, cells within biofilms can be up to 1000x
more resistant to antimicrobial treatment than their planktonic
counterparts (Chandra et al., 2001; Donlan and Costerton, 2002).
The exact microbial composition on any particular VPs is
influenced by several factors including patient diet, lifestyle and
the voice prosthesis management regime to which they subscribe
(Talpaert et al., 2015).
Streptococcal species such as Streptococcus mitis and
Streptococcus sobrinus, Staphylococcal species such as
Staphylococcus aureus (Neu et al., 1994), and Pseudomonas
aeruginosa (Sayed et al., 2012) are among the major bacterial
microorganisms frequently isolated from VPs biofilms. Candida
albicans is reported as the most prevalent fungal colonizer of
a VP surface (Bauters et al., 2002; Buijssen et al., 2012), it is a
commensal yeast that is found on the mucosal surfaces of the
oral cavity, gastrointestinal tract and genitourinary tract of most
healthy individuals (Berman and Sudbery, 2002; Ganguly and
Mitchell, 2011). C. albicans is a dimorphic fungus and biofilm
formation of this organism involves a switch from growing in the
typical budding yeast form to a filamentous hyphal form.
Here we characterize the microflora found on early failing
voice prosthesis from 48 patients within Kent (South East
United Kingdom) over a 5-year period (2011–2016). We
observed that multi-species biofilms form in most cases, with
C. albicans and S. aureus being the most prevalent. We
demonstrate that the high CO2 environment experienced in the
airway promotes C. albicans biofilm formation on VPs, providing
an explanation for its prevalence on these devices. To determine
whether yeast colonization acts as a driver for early VP failure
we devised an evidence based strategy to manage contamination
using a newly developed high-throughput assay that mimics
in situ conditions in combination with drug sensitivity data. We
report results from a 20 patient study that applies our principles
of precision antimicrobial assessment that verifies antifungal
treatment as a highly effective approach to VP lifespan extension.
The study documented voice prosthesis lifespan pre- and post-
management pathway implementation and statistical analyses
confirmed a significant increase in VP lifespan within the patient
cohort. Our guidelines represent a significant advance in both our
understanding of the underlying cause of VP failure and a new
effective method to increase VP lifespan by an average of 2.7-fold.
MATERIALS AND METHODS
Patient Cohort and Voice Prostheses
Biofilms from a total of 159 early failing VPs from 48 patients
(41 males and 7 females; mean age = 69.5 years, range 35–
90 years) were analyzed for microorganism composition over
a 5-year period (2011–2016). All prostheses were removed
from patients attending one of the three main acute hospital
sites within East Kent, United Kingdom: William Harvey
Hospital, Ashford; Canterbury Hospital, Canterbury; Queen
Elizabeth the Queen Mother Hospital, Margate. 38 of these
patients had multiple voice prosthesis failures and were
followed as part of a Candida management guideline impact
study, which documented the voice prosthesis lifespans before
and after implementation of a set of treatment guidelines
designed to limit fungal growth. Treatment guidelines for the
treatment of VPs with anti-fungal drugs were approved by the
East Kent Hospital University Foundation Trust (EKHUFT)
Voice Prosthesis Infection Management Multi-disciplinary team
(MDT), EKHUFT Antimicrobial Stewardship Group, EKHUFT
Drugs and Therapeutics Committee, EKHUFT ENT Audit
Group, EKHUFT Adult Speech and Language Therapy Service,
East Kent Prescribing Group. This study was approved by the
EKHUFT Research and Innovation Department (2018/GAP/20)
in accordance with the Department of Health’s Research
Governance Framework for Health and Social Care and
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EKHUFT Research and Innovation policy. All patient data was
anonymised prior to use in this study.
Please contact the corresponding authors for information
if you wish to start using the Candida Management clinical
guidelines for voice prosthesis management used in this study.
Microorganism Isolation and
Identification
To determine which microorganisms were present, a failed
voice prosthesis was removed from the patient and sealed in
a sterile bag. Upon receipt at the microbiology laboratory,
the voice prosthesis was added to 2 ml saline solution
along with glass beads and vortexed at 2500 rpm for 30 s.
The resulting suspension was plated on chromogenic agar
to facilitate identification of bacterial species. 50 µl of the
suspension was also plated on Sabouraud Dextrose Agar (SDA)
plates (Oxoid, CM0041) containing 100 µg/ml chloramphenicol
(Oxoid, SR0078) to promote the growth of fungal species while
inhibiting bacterial growth. Chromogenic agar and SDA plates
were incubated for 48 h at 37◦C. Bacterial colonies were then
picked from the chromogenic plates and fungal colonies were
picked from the SDA plates, species were identified using




MALDI-ToF mass spectrometry was used to identify species
isolated from failed VPs within this study. Fungal and bacterial
colonies were picked and applied to a steel MALDI target plate
before being overlaid with an α-cyano-4-hydroxycinnamic acid
(4-HCCA) matrix (Sigma-Aldrich, 70990) (Gobom et al., 2001).
MALDI-ToF mass spectrometry was performed using a Bruker
MALDI Biotyper (Bruker) as per the manufacturer’s instructions.
The resulting mass spectra were compared to a reference database
for identification using the MBT Compass and MBT Explorer
Software along with the MBT Compass Library which comprises
approximately 2750 species from 471 microorganism genera.
Antifungal Sensitivity Testing
Antifungal sensitivity testing was performed using the
FungitestTM commercial testing kit (BioRad, 60780) as per
the manufacturer’s instructions. Isolates were assigned sensitive,
intermediate, or resistant based upon the European Committee
on Antimicrobial Sensitivity Testing (EUCAST) breakpoint
recommendations for each antifungal and/or species (European
Committee on Antimicrobial Susceptibility Testing, 2018).
Antibacterial Sensitivity Testing
Antibacterial sensitivity testing was carried out to determine
the minimum inhibitory concentrations (MICs) of clinically
commonly used antibiotics. Isolates were assigned sensitive,
intermediate, or resistant based upon the EUCAST breakpoint
recommendations for each antibiotic and/or species (European
Committee on Antimicrobial Susceptibility Testing, 2019).
Scanning Electron Microscopy (SEM)
of Voices Prosthesis Surfaces
Segments were taken from the valve and flange of a Provox Vega
voice prosthesis and mounted onto 12.5 mm aluminum SEM
specimen stubs (Agar Scientific, AGG301) with superglue. The
surfaces were imaged at ambient temperature with a Hitachi
S-3400N scanning electron microscope, using the variable
pressure scanning electron microscopy (VP-SEM) mode with a
chamber pressure of 30 Pa and accelerating voltage of 10 kV.
The backscattered electron (BSE) detector in conjunction with
the energy dispersive X-ray spectroscopy (EDS) detector was
used throughout with a working distance of 10 mm. The
acquisition software was Oxford Instruments INCA and images
were exported directly from this.
Atomic Force Microscopy (AFM) of Voice
Prosthesis Surfaces
Segments were taken from the valve and flange of a Provox
Vega voice prosthesis and mounted onto 15 mm AFM specimen
disks (Agar Scientific, F7003) with superglue. These surfaces were
imaged at ambient temperature using a Bruker Multimode 8
scanning probe microscope with a Nanoscope V controller, using
the ScanAsyst peak-force tapping mode with a 50 µm × 50 µm
scan area and a 700 nm scan height. SCANASYST-AIR (Bruker)
silicon nitride cantilevers (tip height of 2.5–8.0 µm, nominal tip
radius of 2 nm) with a nominal spring constant of 0.4 N/m and
a resonance frequency of 70 kHz were used throughout. The
image acquisition software was Nanoscope 8.15 R3sr5 and the
processing software was Nanoscope Analysis.
Candida Strains and Growth Media
Candida strains (Supplementary Table S3) were routinely grown
at 30◦C in yeast peptone dextrose (YPD) media (2% peptone
(BD Bacto), 2% D-glucose (Fisher Scientific), 1% yeast extract
(BD Bacto). For the biofilm growth assays, Candida biofilms were
grown at 37◦C in RPMI-1640 media (Sigma-Aldrich, R8755)
supplemented with 80 µg/ml uridine (Sigma-Aldrich, U3750).
Candida strains were maintained in YPD + 20% glycerol at
−80◦C for long-term storage and revived at 30◦C on YPD + 2%
Technical Agar (Oxoid) plates.
In vitro Biofilm Growth Assays
To investigate fungal biofilm formation and its treatment on
VPs a high-throughput assay was developed. C. albicans biofilms
were grown on a PDMS silicone elastomer (Provincial Rubber,
S1). The silicone was cut into 1 cm2 squares and placed in clips
in a modified 24-well plate lid (Academic Centre for Dentistry
Amsterdam, AAA-model) so they could be suspended in media
within a sterile 24-well plate (Greiner Bio-one, CELLSTAR,
662160). Silicone squares were incubated in 1 ml 50% donor
bovine serum (DBS) (Gibco, 16030074) for 30 min at 30◦C,
then washed twice with 1 ml Phosphate-Buffered Saline (PBS –
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4,
pH 7.4) to remove excess DBS. Candida strains were inoculated
into a test tube containing 5 ml YPD media and placed in a 30◦C
orbital shaking incubator with constant shaking at 180 rpm for
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18 h. OD600 measurements were taken and a volume of overnight
culture corresponding to OD600 = 1.0 (3 × 107 CFU/ml) was
removed. These cells were pelleted by centrifugation at 4000 rpm
for 5 min at which point the supernatant was discarded. The
resultant pellet was re-suspended in 5 ml PBS to wash and
centrifuged again at 4000 rpm for 5 min. The PBS supernatant
was discarded and the pellet re-suspended in fresh PBS (at an
OD600 of 1.0). The OD600 1.0 standard cell suspension was added
to wells (1 ml per well) in a pre-sterilized 24-well plate and
the lid with the silicone squares attached was placed on top so
the silicone squares protruded into the cell suspension. These
plates were then incubated at 37◦C (in either 0.03% CO2 or 5%
CO2) without shaking for 90 min to allow cell attachment to the
silicone. After the attachment phase, the silicone squares were
washed twice with 1 ml PBS to remove any unattached cells and
transferred to 1 ml RPMI-1640 media (Sigma-Aldrich, R8755).
They were then incubated at 37◦C (in either 0.03% CO2 or 5%
CO2) without shaking for up to 48 h to allow biofilm maturation.
Growth of biofilms on the surface of a sterile VP was conducted
using the same protocol.
Biofilm Quantification via XTT Assay
Biofilm growth was quantified using an XTT assay (Kuhn et al.,
2002). Biofilms were washed twice with 1 ml PBS to remove
any planktonic cells before proceeding to quantification. After
washing, the biofilms were transferred to a new pre-sterilized
24-well plate (Greiner Bio-one, CELLSTAR, 662160) containing
30 µg/ml XTT labeling reagent (Roche, 11465015001) and
incubated at 37◦C for 4 h. After incubation, the biofilms were
removed from the 24-well plate and the absorbance of the
remaining XTT labeling reagent was measured at 492 nm using a
BMG LABTECH FLUOstar Omega plate reader machine.
Antifungal Treatment of Biofilms
Biofilms were seeded on silicone elastomer sections as described
above and grown in RPMI-1640 for 24 h at 37◦C. The
biofilms were then transferred to fresh RPMI-1640 media
containing an antifungal, either; Fluconazole, Miconazole, or
Nystatin at indicated concentrations. Fluconazole (Santa Cruz
Biotechnology, sc-205698) was made as a 50 mg/ml stock solution
in ethanol and diluted in RPMI-1640 final concentrations of
128 and 32 µg/ml. Miconazole (Santa Cruz Biotechnology, sc-
205753) was made as a 50 mg/ml stock solution in DMSO
and also diluted in RPMI-1640 to final concentrations of 32
and 128 µg/ml. Nystatin (Santa Cruz Biotechnology, sc-212431)
was made as a 5 mg/ml stock solution in DMSO and diluted
in RPMI-1640 to final concentrations of 2 and 8 µg/ml.
Drug vehicle controls (0.25% ethanol for Fluconazole, 0.25%
DMSO for Miconazole, and 0.15% DMSO for Nystatin) were
used to ensure the solvents were not affecting biofilm growth.
The biofilms matured in the RPMI-1640 media containing
the select antifungal for a further 24 h at 37◦C in both
0.03 and 5% CO2 before proceeding to quantification via the
XTT assay. Experiments were performed in biological and
technical triplicate.
Mixed Species Biofilm Competition
Assays
Biofilms were set up as described previously, except that for
mixed biofilms C. albicans and C. parapsilosis clinical isolate
overnight cultures were each counted and adjusted to 1.5 × 107
CFU/ml to give a 3 × 107 CFU/ml overall inoculum (equivalent
to OD600 of 1.0) for the 90 min attachment phase. After
attachment, the silicone squares were washed twice with 1 ml PBS
to remove any unattached cells and transferred to 1 ml RPMI-
1640 media (Sigma-Aldrich, R8755). They were then incubated
at 37◦C in both 0.03% CO2 or 5% CO2 without shaking for 48 h
to allow biofilm maturation before proceeding to quantification
via the XTT assay. Experiment was performed in biological and
technical triplicate.
Biofilm Composition Analysis via
Chromogenic Agar
Silicone squares with biofilms on them were dropped into 2 ml
PBS and vortexed for 10 s at 2500 rpm to release the biofilm cells
from the surface. The resulting biofilm cell suspension was plated
on Candida Ident Agar (Fluka Analytical, 94382) in triplicate
(200 µl per plate). The chromogenic agar plates were incubated
at 30◦C for 48 h, at which point photographs of the plates were
taken. C. albicans colonies appeared green and C. parapsilosis
colonies stayed white on the Candida Ident Agar plates.
Analysis of Voice Prosthesis Lifespans
Voice prosthesis lifespans at the Speech and Language Therapy
Centre at the Kent and Canterbury Hospital were investigated
over the course of 8 years (2010–2018). In total, 38 patients
had their voice prosthesis lifespan documented. However, 18
patients were removed from further analysis due to a lack
of adherence to the guidelines, moving out of the hospital
catchment area resulting in incomplete data entries, or simply
not enough VPs failures/changes in the time period. The voice
prosthesis lifespans of the remaining 20 patients, before and after
the implementation of our treatment pathway, were analyzed
using the Online Application for Survival Analysis 2 (OASIS 2)
platform (Kim et al., 2016). In total, 143 VPs before and 176
after implementation of the pathway were included in this study.
Kaplan–Meier survival curves were plotted and log-rank tests
performed to statistically compare device lifespans before and
after the treatment pathway. Wilcoxon Signed-Rank tests were
also carried out to determine if the pathway effect was significant
when taking into account the inherent differences in device
lifespan from patient to patient. For all analyses, the significance
level (α) was 0.05.
RESULTS
Analysis of Microorganisms Found on
Early Failing Voice Prostheses
Staphylococcus aureus was the most frequently isolated bacterial
species (Figure 1B), being found on multiple early failing
VP (Figures 1B,C). This finding is in line with previous
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FIGURE 1 | The range and distribution of bacterial species found on voice prostheses within this study. (A) An example of a failed voice prosthesis removed from a
patient. Note the ring of colonization on the prosthesis hood around the valve mechanism. (B) Bar graph representation of absolute numbers of times each bacterial
species was isolated from 159 early failing VPs. (C) Pie chart representation of percentage of total bacteria isolated from 159 early failing VPs.
studies that also identified S. aureus as the prevalent bacterial
organism found within VP biofilms (Neu et al., 1994; van
Weissenbruch et al., 1997). However, S. aureus was one of several
Staphylococcal species identified, the others being identified
at lower frequencies included Staphylococcus epidermidis and
Staphylococcus schleiferi (Figures 1B,C). We also identified the
S. aureus strain methicillin-resistant S. aureus (MRSA) on 5 VPs
and counted these separately from the rest of the S. aureus isolates
(Figures 1B,C). P. aeruginosa was the second most frequent
bacterial species found on early failing VPs (Figures 1B,C).
Previous studies have also identified P. aeruginosa as a prevalent
bacterial species found within VP biofilms (Sayed et al., 2012).
Several Streptococcus species were also identified, but at a low
frequency, including Streptococcus milleri, Streptococcus mitis,
and Streptococcus intermedius (Supplementary Table S1).
Yeast species were isolated from the vast majority of the 159
early failing VPs; 107 (67.3%) were colonized by a single yeast
species, 37 (23.3%) were colonized by multiple yeast species,
and just 15 (9.4%) showed no yeast species presence. In total,
178 yeast isolates were identified and 168 (94.4%) of these
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were Candida species, the remaining 10 fungal isolates were
made up of Saccharomyces cerevisiae (8) and Pichia manshurica
(2). S. cerevisiae and P. manshurica isolates were normally
found alongside Candida species (62.5 and 100% respectively).
The most frequently isolated yeast species was C. albicans
(Figures 2A,B). This is in line with previous studies which
identified C. albicans as the yeast species most commonly found
on VPs (Everaert et al., 1997; Bauters et al., 2002; Buijssen et al.,
2012). The non-albicans Candida isolates constituted 44.4% of all
fungal isolates, with Candida glabrata being the most common of
these (Supplementary Table S2).
The same bacterial and fungal species were frequently isolated
from sequential VPs removed from the same patient implicating
a common pattern of biofilm establishment. In total, 38 of the 48
patients had more than one voice prosthesis failure during the
course of the study. 30 of these (78.9%) had the same bacterial
species present on at least 2 VPs while 29 (76.3%) had the same
fungal species on at least 2 VPs. 25 of the 29 patients which had
reoccurring fungal species also had the same bacterial species on
at least 2 VPs. The most commonly reoccurring fungal species
was C. albicans, being found on multiple VPs within 18 patients.
It is worth noting that fungal and bacterial species were often
found together on early failing VPs, 134 (84.3%) had at least one
species of each present. The two most numerous species in this
study, S. aureus and C. albicans, were the most commonly co-
isolated species, being found together on 60 (37.7%) VPs. It was
very rare for only fungal species to be present; only 10 (6.3%) VPs
harbored solely fungal species and intriguingly all of these were
either the first or second VP failure of their respective patients.
The significance of this, if any, is yet to be determined. The two
most commonly co-isolated fungal species were C. albicans and
C. glabrata which were found together on 17 (10.7%) VPs.
It is of importance to highlight that the most prevalent
voice prosthesis colonizing organisms within our patient cohort
FIGURE 2 | The range and distribution of fungal species found on early failing VP. (A) Bar graph representation of absolute numbers of times each yeast species was
isolated from 159 early failing VPs. (B) Pie chart representation of percentage of total yeast isolated from 159 early failing VPs.
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correlate with previous findings. This suggests that an effective
treatment plan designed to tackle biofilm formation on VP in our
cohort may have wide-reaching applicability.
Factors Promoting Microbial
Colonization of Voice Prostheses
Our routine examination of early failing VPs often suggested
concentration of microbial growth on certain regions of the
device surface (Figure 1A). We investigated surface topography
using atomic force and scanning electron microscopy as
roughness has been shown to be an important driver of
colonization (Radford et al., 1998; Nevzatog˘lu et al., 2007). The
flange (Figure 3A) of the device exhibited a significantly rougher
topography than the valve which appeared smooth using these
high resolution techniques (Figures 3B,C). The roughness of the
flange was particularly evident in the AFM 3D plot of its surface
(Figure 3D). In line with previous studies, this may suggest
FIGURE 3 | Atomic force and scanning electron microscopy surface topography of the valve and esophageal flange of the Provox Vega voice prosthesis. (A) The
Provox Vega voice prosthesis. (B) SEM images of the valve and inner-side of the prosthesis hood were taken at x120 magnification. The scale bars represent
700 µm. (C) AFM images of the valve and esophageal flange were taken of 50 µm × 50 µm surface areas with a scan height of 700 nm. (D) AFM 3D plot of a
50 µm × 50 µm area of the esophageal flange. Z-axis is 0–1 µm. Several images were taken and representative examples are presented.
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that the flange, specifically the valve-flange interface, provides a
more likely site for initial attachment (Leunisse et al., 2001). This
proposition is also consistent with our observations that failed
VPs often exhibit heavy colonization on the flange, particularly
at the rougher inner edge where the flange interfaces with the
valve (Figures 1A, 3Bii).
Due to the high CO2 levels (∼5%) experienced in the airway as
a result of exhaled breath (Tsoukias et al., 1998), we contemplated
whether CO2 could be exerting an effect on C. albicans biofilm
formation in the voice prosthesis scenario. Indeed, when seeded
onto a voice prosthetic surface, C. albicans has increased biofilm
growth in 5% CO2 after 24 h than in atmospheric air (Figure 4).
Constant exposure of the valve mechanism and parts of the
esophageal flange to exhaled air may therefore contribute to the
prevalence of C. albicans colonization upon VPs.
C. parapsilosis Does Not Have a
Competitive Advantage Over C. albicans
in Biofilm Establishment
We observed that Candida parapsilosis was rarely co-isolated
with another Candida species. Of the 14 VPs which harbored
C. parapsilosis, only 1 also had another Candida species present.
This is a stark contrast to other Candida species, such as
C. glabrata which was found on 23 VPs, 19 of which also had
additional Candida species. This led us to investigate whether
C. parapsilosis exhibited a competitive advantage over C. albicans
with regards to biofilm growth. A C. parapsilosis clinical isolate
found as the sole yeast species on a failed VP was selected for this
investigation. Biofilms were seeded using equal cell numbers of
the C. albicans and C. parapsilosis clinical isolates either alone or
in combination and incubated for 48 h to mature. Overall biofilm
growth was analyzed by measuring the metabolic activity of the
biofilms using the XTT colorimetric assay (Kuhn et al., 2002)
(Figure 5). The proportions of C. albicans and C. parapsilosis
cells were then analyzed by removing biofilms from the silicone
surface and plating the resulting cell suspension on chromogenic
agar (Supplementary Figure S1). Strikingly, while the C. albicans
G-3065 clinical isolate was able to form a robust biofilm on the
silicone surface, the C. parapsilosis G10402 clinical isolate was
not (Figure 5). Moreover, when these two clinical isolates were
seeded together, the resultant biofilm was composed primarily
of C. albicans cells (Supplementary Figure S1). In addition,
while C. albicans biofilms were significantly increased when
grown in the presence of increased CO2 this was not observed
for C. parapsilosis. These data suggest that the identification of
C. parapsilosis in isolation on failed VPs is unlikely to arise from
a competitive advantage over C. albicans.
Antimicrobial Sensitivity of Clinical
Isolates
The sensitivities of the five most common bacterial species found
on early failing VP to an example antibiotic from the five major
antibiotic classes (Coates et al., 2011) are reported (Table 1).
Only 10 (8.5%) of the most common bacterial isolates tested for
sensitivity against the β-lactam antibiotic amoxicillin were judged
to be sensitive, and these were all S. aureus isolates. All of the
FIGURE 4 | Candida albicans biofilm forming on the flange of a voice prosthesis in vitro in both atmospheric air and elevated CO2 conditions. C. albicans biofilm
formation was assessed on a Provox Vega VP at 37◦C under atmospheric air and elevated CO2 conditions that mimic exhaled breath. Images were collected after
24 h at x8 and x100 magnification. The experiment was repeated three times and representative images are presented.
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FIGURE 5 | In vitro biofilm assay using C. albicans and C. parapsilosis early
failing VP clinical isolates. Biofilms were seeded and grown for 48 h to mature,
the resulting biofilms were quantified using the XTT assay which produces a
red product that can be measured spectrophotometrically at 492 nm (higher
cell number = higher absorbance). The C. albicans G-3065 clinical isolate
makes bigger biofilms than the C. parapsilosis G10402 clinical isolate, and
this biofilm formation is influenced by CO2 concentration. The graph
represents three independent experiments each containing triplicates, error
bars denote Standard Deviation. Paired two-tail t-tests were carried out:
*p < 0.05, **p < 0.01, ***p < 0.001, n.s. = not significant.
P. aeruginosa, S. marcescens, MRSA, and K. pneumoniae isolates
tested for amoxicillin sensitivity were resistant. 76 (74.5%) were
deemed to be sensitive to the macrolide erythromycin, with
a significant number of S. aureus isolates being found to be
resistant. The majority of the common bacterial isolates were
sensitive to the fluoroquinolone Ciprofloxacin with 111 (93.3%)
being judged as sensitive, however, all of the MRSA isolates
tested were resistant to Ciprofloxacin. Likewise, a high number
of isolates were sensitive to Tetracycline (104–87.4%), but this
antibiotic did not exhibit good activity against the P. aeruginosa
and S. marcescens isolates with 5 (83.3%) of both species being
resistant. Finally, 115 (96.6%) of the common bacterial isolates
tested were sensitive to the aminoglycoside Gentamicin, this was
in fact the most effective antibiotic tested in this study (Table 1).
The sensitivities of the five most frequently isolated fungal
species in this study to Fluconazole, Miconazole and Nystatin,
three commonly used antifungals in the clinical setting, are
reported (Table 2). Of the 168 Candida isolates, 155 were tested
for Fluconazole sensitivity and 139 of these were found to be
sensitive (89.7%). Moreover, 123 of the Candida isolates were
tested for Miconazole sensitivity and 107 were sensitive (87.0%).
Finally, 129 of the Candida isolates were tested for Nystatin
sensitivity and 126 of these were found to be sensitive (97.7%).
Nystatin therefore appeared to be the most effective antifungal
with regards to inhibition of growth of Candida species obtained
from early failing VPs in this patient cohort.
Antifungal Sensitivity of C. albicans
Clinical Isolates Within Biofilms
The antifungal drugs Nystatin, Miconazole, and Fluconazole are
commonly used as agents to treat fungal colonization of the
ear, nose, and throat. We therefore tested their efficacy against
C. albicans biofilms grown from isolates recovered from early
failing VPs. The clinical isolates displayed higher resistances
to Fluconazole and Miconazole compared to Nystatin when
growing as biofilms (Table 3). Moreover, this azole resistance
was significantly increased in biofilms grown in high CO2
environments (Supplementary Figure S2). For instance, G-
8424 biofilms grown in 0.03% CO2 had an average decrease
in XTT activity of 59% relative to the untreated control upon
treatment with 32 µg/ml Fluconazole (p < 0.001), whereas
there was no significant decrease in relative XTT activity in
the 5% CO2 G-8424 biofilms (Table 3 and Supplementary
Figure S2). This was also true for the 128 µg/ml Miconazole
treatments in all three isolates (Table 3 and Supplementary
Figure S3). Furthermore, despite the fact that 0.03 and 5%
CO2 G-1625 biofilms both displayed significant decreases in
relative XTT activity upon Fluconazole treatment, the relative
XTT activity was still significantly higher in the biofilms grown in
5% CO2 (Supplementary Figure S2). Nystatin sensitivities were
generally independent of CO2 concentration (Figure 6). The G-
3065 and G-8424 clinical isolate biofilms were more resistant to
Fluconazole and Miconazole than the G-1625 isolate, however, all
isolate biofilms exhibited good sensitivity to Nystatin (Table 3).
Based on these data, we conclude that Nystatin is the most
potent against C. albicans biofilms on silicone surfaces and also
offers the greatest protection against the CO2 biofilm activation.
However, Fluconazole and Miconazole are still both efficacious
against some isolates. This approach, which extended current
drug susceptibility testing practice to better represent in vivo
biofilm growth conditions, was crucial in our decision to make
use of Nystatin as the lead compound in the development of
antifungal treatment guidelines.
Development and Clinical Testing of
Antifungal Treatment Guidelines (ATG) to
Extend VP Lifespan
Although VP biofilms are likely to be formed from several
species we hypothesized that an antifungal approach to reduce
colonization may effective in extending device lifespan. The
rationale behind this was based on three observations. First,
yeast contamination contributes significant biomass which in
turn is more likely to impair valve function. Second, the elevated
physiological CO2 environment in which a VP sits promotes
biofilm growth of the most commonly isolated yeast, C. albicans.
Third, since other commonly isolated bacteria, such as S. aureus
and P. aeruginosa have been reported to use Candida hyphae as
a scaffold to attach to during biofilm formation (Harriott and
Noverr, 2009), it may be the case that antifungal treatment also
attenuates the bacterial colonization.
The antifungal drugs selected for treatment were chosen
based upon the fungal sensitivity data with Nystatin being
demonstrated to be the most effective as it had the lowest levels
of resistance (Table 2). Previous studies have also identified
that most non-albicans Candida species have higher azole MICs
(Ribeiro et al., 2001; Singh et al., 2002), whereas all Candida
species have low in vitro Nystatin MICs (Nenoff et al., 2016).
Moreover, C. albicans sensitivity to Nystatin when in a biofilm
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TABLE 1 | Antibiotic sensitivity of the five most common bacterial species isolated from early failing VPs.
Species Total number of isolates tested Number of isolates in each category (%)
Sensitive Intermediate Resistant
Amoxicillin
Staphylococcus aureus 96 10 (10.4) 0 76 (79.2)
Pseudomonas aeruginosa 6 0 0 6 (100)
Serratia marcescens 6 0 0 6 (100)
MRSA 5 0 0 5 (100)
Klebsiella pneumoniae 5 0 0 5 (100)
Total 118 10 (8.5) 0 98 (83.1)
Erythromycin
Staphylococcus aureus 97 71 (73.2) 1 (1.0) 25 (25.8)
Pseudomonas aeruginosa 0 – – –
Serratia marcescens 0 – – –
MRSA 5 5 (100) 0 0
Klebsiella pneumoniae 0 – – –
Total 102 76 (74.5) 1 (1.0) 25 (24.5)
Ciprofloxacin
Staphylococcus aureus 97 95 (97.9) 0 1 (1.0)
Pseudomonas aeruginosa 6 5 (83.3) 0 1 (16.7)
Serratia marcescens 6 6 (100) 0 0
MRSA 5 0 0 5 (100)
Klebsiella pneumoniae 5 5 (100) 0 0
Total 119 111 (93.3) 0 7 (5.9)
Tetracycline
Staphylococcus aureus 97 95 (97.9) 0 2 (2.1)
Pseudomonas aeruginosa 6 0 0 5 (83.3)
Serratia marcescens 6 0 1 (16.7) 5 (83.3)
MRSA 5 5 (100) 0 0
Klebsiella pneumoniae 5 4 (80) 0 1 (20)
Total 119 104 (87.4) 1 (0.8) 13 (10.9)
Gentamicin
Staphylococcus aureus 97 93 (95.9) 0 4 (4.1)
Pseudomonas aeruginosa 6 6 (100) 0 0
Serratia marcescens 6 6 (100) 0 0
MRSA 5 5 (100) 0 0
Klebsiella pneumoniae 5 5 (100) 0 0
Total 119 115 (96.6) 0 4 (3.4)
The number of sensitive, intermediate, and resistant isolates based upon EUCAST breakpoint recommendations are given for the five most commonly isolated
bacterial species.
appears to be unaffected by CO2 level (Figure 6). Our antifungal
voice prosthesis management guidelines involve determining
the identity and antimicrobial sensitivities of microorganisms
present on a failed VP. Based on the antifungal sensitivities
of the colonizing fungal species, a course of antifungals (most
commonly Nystatin) is suggested and prescribed for topical
application directly on the VP.
To test the effectiveness of our antifungal approach to
managing VP data from 38 patients was assessed. VP lifespan
data from the patient cohort before and after their placement
on the ATG was assessed. Over the course of the study,
18 patients were removed from further analysis because of
either; concerns over a lack of adherence to the ATG, moving
out of the hospital catchment area resulting in incomplete
data entries, or insufficient VP replacement data. This left
20 patients with complete VP lifespan data entries before
and after guideline implementation on which to conduct
statistical analyses.
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TABLE 2 | Antifungal sensitivity of the five most common Candida species isolated from early failing VPs.
Species Total number of isolates tested Number of isolates in each category (%)
Sensitive Intermediate Resistant
Fluconazole
Candida albicans 83 81 (97.6) 2 (2.4) 0
Candida glabrata 23 21 (91.3) 2 (8.7) 0
Candida tropicalis 15 15 (100) 0 0
Candida parapsilosis 14 12 (85.8) 0 2 (14.3)
Candida krusei 9 1 (11.1) 2 (22.2) 6 (66.7)
Total 144 130 (90.3) 6 (4.2) 8 (5.5)
Miconazole
Candida albicans 62 59 (95.1) 3 (4.9) 0
Candida glabrata 19 19 (100) 0 0
Candida tropicalis 13 7 (53.9) 6 (46.1) 0
Candida parapsilosis 9 4 (44.4) 4 (44.4) 1 (11.1)
Candida krusei 9 8 (88.9) 1 (11.1) 0
Total 112 97 (86.6) 14 (12.5) 1 (0.9)
Nystatin
Candida albicans 65 64 (98.5) 0 1 (1.6)
Candida glabrata 20 18 (90.0) 1 (5.0) 1 (5.0)
Candida tropicalis 15 15 (100) 0 0
Candida parapsilosis 9 9 (100) 0 0
Candida krusei 9 9 (100) 0 0
Total 118 115 (97.4) 1 (0.9) 2 (1.7)
The number of sensitive, intermediate, and resistant isolates based upon EUCAST breakpoint recommendations are given for the five most commonly
isolated yeast species.
TABLE 3 | Antifungal sensitivity of biofilms of three C. albicans clinical isolates from early failing VPs.
Antifungal C. albicans G-3065 C. albicans G-8424 C. albicans G-1625
0.03% CO2 5% CO2 0.03% CO2 5% CO2 0.03% CO2 5% CO2
Fluconazole
32 µg/ml + + ++ − +++ ++
128 µg/ml + + +++ − +++ ++
Miconazole
32 µg/ml − − − − − +
128 µg/ml ++ − +++ − +++ +
Nystatin
2 µg/ml +++ +++ − + + +
8 µg/ml +++ +++ ++ +++ +++ +++
Action of antifungals was measured via the XTT assay activity relative to untreated in both 0.03 and 5% CO2: − >80%, + 60–80%, ++ 40–60%, +++ <40%.
Throughout the 8 year course of the study, the lifespan of
319 VPs (143 before and 176 after guidelines) across the 20
patient cohort were analyzed. These 319 VPs represented all
the changes for the 20 patients when the removed VP was
replaced by the same model of the same size. This ensured
there were no external factors such as VP surface/surface area
influencing the results. We also included all changes and not
just those specifically attributed to the presence of Candida
growth to remove bias.
Overall, implementation of the ATG resulted in a significant
(p < 0.001) increase in VP lifespan within our patient
cohort (Figure 7A). Importantly, this lifespan increase was not
dependent on VP manufacturer/model as both the Blom-Singer
Classic and the Provox Vega (the two most common VPs in
this study) exhibited similar increases in lifespan (Figure 7B).
It is also important to highlight that the lifespans of these two
models were not significantly different before or after the pathway
implementation (Figure 7B).
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FIGURE 6 | Nystatin sensitivities of C. albicans clinical isolate biofilms. Biofilms were seeded and grown for 24 h before addition of Nystatin, they were then grown
for a further 24 h before quantification using the XTT assay. The relative XTT activity is presented with the 0.03% CO2 biofilms being normalized to the 0.03% CO2
untreated control and the 5% CO2 biofilms being normalized to the 5% CO2 untreated control. This prevents the general higher growth of 5% CO2 biofilms
impacting the analysis. Graphs represent three independent experiments each containing triplicates, error bars denote Standard Deviation. Two-way ANOVAs
followed by a Tukey test for multiple comparisons were carried out: *p < 0.05, **p < 0.01, ***p < 0.001. Stars directly above the bars indicate a significant difference
to untreated in the same CO2 environment.
Although there was variation in average post-pathway VP
lifespan increase between patients, the majority of the patients
in our cohort enjoyed an overall increase in device lifespan
(Figure 8A). Two patients did not exhibit an increase in
VP lifespan, instead having a slight decrease of −2.4 and
−45.5 days respectively (Figure 8A). However, these two
patients had long-lived VPs on average (97.1 and 193.3 days
respectively) in comparison with the rest of the cohort prior to
the introduction of the new antifungal clinical guidelines. This
was particularly evident for patient 16 whose VPs were already
lasting longer than the post-pathway mean lifespan across all
patients. Thus, the treatment guidelines may be of most benefit
to patients who are experiencing early failing VP. The mean VPs
lifespan before guideline implementation was 71.9 days and this
increased to 192.0 days after implementation of the antifungal
management pathway representing an average 2.7-fold increase
in lifespan (Figure 8B).
We did not identify any cases of increased drug resistance to
antifungal application within the study. However, our guidelines
recommend a 6 months (180 days) limit before VP change.
This length of time was chosen primarily to ensure that the VP
remains structurally sound. Before ATG use only 8 VPs (5.6%)
reached this target across all 20 patients, while post-ATG 63 VPs
(35.8%) lasted at least 180 days (Figure 7A). It is worth noting
that after the treatment guidelines were implemented, several
VPs were being routinely changed because they had been in situ
for >6 months and not because they had actually failed. The full
set of guidelines can be obtained by contacting the authors and
are briefly summarized in Figure 8C.
DISCUSSION
The colonization of VP by mixed biofilms has been reported as
a potential cause for their early failure. However, a mechanistic
understanding as to such biofilms may drive early failure and
to what extend bacterial or fungal presence underlies failure
is not well-understood. In this study we sought to investigate
whether an antifungal treatment regime would provide an
effective option for prevention early VP failure. Using a dedicated
extraction protocol combined with high-powered microbiology
identification we confirmed Candida albicans as the most
prevalent fungal microorganism found on early failing VP. Our
findings are in-line with previous studies where C. albicans was
the most common fungal species isolated from VP (Buijssen
et al., 2012). It is however likely that differences in the
identification methods used, different patient demographics or
lifestyles and different lifestyles or dietary habits will impact upon
the microbial colonization of VP. For instance, Chaturvedi et al.
(2014) found that C. tropicalis was the most prevalent fungal
species colonizing VP within an Indian patient cohort. The high
consumption of dairy products such as yogurt and buttermilk
in India has been proposed to influence biofilm growth on VPs.
For example, the presence of Streptococcus thermophilus and
Lactobacillus in yogurt may reduce biofilm formation (Havenaar
and Huis In’t Veld, 1992; Busscher et al., 1997b), while the
high lactoferrin content (also found in saliva) in buttermilk has
antibacterial and antifungal properties against organisms such as
C. albicans and Streptococcus mutans (Soukka et al., 1991, 1992;
Nikawa et al., 1993).
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FIGURE 7 | Kaplan–Meier survival curves showing the voice prosthesis in situ
lifespans before and after implementation of our antifungal treatment pathway.
(A) Device lifespans were documented before and after implementation of the
ATG. Kaplan–Meier survival curves were plotted using the OASIS2 online
platform and a log-rank test was used to compare the survival curves:
p < 0.001. Red line is at 180 days lifespan which we targeted as the ideal
lifespan to achieve. (B) After lifespan analysis across all devices was
performed, the lifespans were categorized into groups depending on which
VP model a patient was using. Kaplan–Meier survival curves were again
plotted using the OASIS2 online platform and log-rank tests were used to
compare them: Blom-Singer Classic, Before vs. After; p < 0.001. Provox
Vega, Before vs. After; p < 0.001.
Our study found S. aureus as the most prevalent bacterial
species on failed VPs, present on 64.2% of VPs, and was
frequently found in combination with one or more Candida
species. This may be expected as S. aureus is a member of the
normal oral and perioral microbiota (McCormack et al., 2015).
Moreover, it is the third most commonly isolated organism
with C. albicans in poly-microbial infections (a significant
proportion of which are nosocomial infections) (Klotz et al.,
2007). Synergistic relationships between S. aureus and C. albicans
have previously been documented. S. aureus is poor at forming
biofilms on its own, however, it has been suggested that the
hyphal C. albicans cells provide a scaffold on which the bacteria
can attach within a poly-microbial biofilm (Harriott and Noverr,
2009). S. aureus has been proposed attach to C. albicans hyphae
as they penetrate epithelial layers and this has been proposed
as relevant for the invasion of human tissues during infection
(Schlecht et al., 2015). Within a mixed biofilm, S. aureus cells
have also been shown to become coated in C. albicans matrix
material, enhancing its antibiotic resistance (Kong et al., 2016).
Furthermore, S. aureus and C. albicans mixed biofilms can
withstand higher shear stresses than pure C. albicans biofilms
(Lin et al., 2013). Given the high frequency with which these
two microorganisms are found together, along with the synergy
they have been previously shown to exhibit, their inter-species
relationship in with respect to biofilm formation on medical
implant devices requires further investigation. However, it is
quite plausible that by treating fungal contamination we may also
decrease the burden of important bacterial pathogens, such as
S. aureus on medical devices such as VPs. The potential impact of
this relationship is highlighted by the fact co-infection results in
increased mortality in mouse models than either microorganism
alone (Carlson, 1982, 1983).
We have demonstrated that the lifespan of VP can
be significantly increased by applying a highly effective
personalized antimicrobial treatment regime focusing on
Candida colonization, without directly treating the bacterial
colonization. Initially we hypothesized that as VP failure
occurs as a result of valve blockage then tackling the more
significant biomass caused by yeast contamination then we
may see better results than attempting to treat bacterial
growth. However, our data also suggest that the rougher
silicone surfaces of the VP and more significantly the high
CO2 environment within exhaled breath can promote Candida
biofilm establishment. Another important reason for tackling
yeast contamination is that C. albicans has been shown to
be able to degrading silicone rubber (Buijssen et al., 2012)
which may contribute further to device failure. An antifungal
approach may also be advantageous because bacteria such as
S. aureus and P. aeruginosa have been reported to attach to
Candida hyphae during biofilm formation (Harriott and Noverr,
2009), meaning antifungal treatment may also attenuate the
bacterial colonization.
Prior to implementation of our VPs management pathway,
the average in situ lifespan of VPs within our patient cohort was
71.9 days. This is similar to a recent large-scale study of voice
prosthesis lifespans in the U.S. by Lewin et al. (2017) which found
an average lifespan of 86 days . While being slightly less than
a study by Kress et al. (2014) which found an average lifespan
of 108 days. The average device lifespan within our patient
cohort increased to 192 days after clinicians started following
the management guidelines – a 270% increase. Importantly, the
increase in lifespan was not affected by the make or model
of VP within the study group, suggesting that this treatment
regime may be applicable to a broad range of patients. The
actual lifespan of VPs post-pathway may be higher than the
192 days reported here, as we recommended the clinicians at the
Kent and Canterbury Hospital Speech and Language Therapy
Centre change VPs prophylactically after 6 months (180 days)
in situ. This ensures there is no biofilm formation around the
TEP as well as no structural deterioration of the device due to
mechanical stress and the constant application of antifungals.
It should be noted that two of our patients did not experience
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FIGURE 8 | The antifungal treatment guidelines along with its effects on voice prosthesis lifespan within each patient. (A) Dumbbell chart representation of the mean
VP lifespan difference after guideline implementation for each of the 20 patients. (B) Box plot representation of VP in situ lifespans before and after guideline
implementation, Wilcoxon Signed-Rank test: ***p < 0.001. (C) Summary of the treatment pathway. As of January 2019, this management pathway has been
distributed to 34 different speech and language therapy centers (32 in the United Kingdom, 2 internationally) upon request.
an increase in VP lifespan while using the antifungal treatment
guidelines; such a result may be expected within such a multi-
factorial clinical scenario. In both cases the patients exhibited
relatively long lived VPs before treatment began, and these
serve to highlight the importance of patient monitoring and
that fungal colonization may not be the cause of early VP
failure in every case.
CONCLUSION
Candida albicans was the most prevalent fungal species found on
failed VPs within our patient group and we have demonstrated
that the topical application of antifungals significantly extends
voice prosthesis lifespan in the majority of patients. Our anti-
fungal treatment guidelines have been fully ratified by the
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relevant EKHUFT NHS committees and have distributed
widely throughout the United Kingdom. Given that several
studies have identified similar microorganisms as predominant
colonizers of VP it is possible that our ATG protocol may
be widely applied and at time of submission it has been
distributed to 34 speech and language therapy centers (32
in the United Kingdom and 2 internationally). Given the
success of this approach it will be imperative to investigate
the use of precision antifungal methodologies to tackle biofilm
formation on a wider range of medical devices and tubing
as a means to reducing infection, morbidity and mortality
associated with their use.
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